• PHARMACEUTICALS AND HEALTHCARE PHARMACEUTICALS AND HEALTHCARE

    Pharmaceutical and healthcare are collectively a highly important business sector for China Grand Enterprises, INC. It includes chemical pharmaceuticals, biopharmaceuticals, Chinese patent medicines, Chinese medicinal materials, Chinese herbal decoction, medical devices, medical cosmetic, pharmacies, chain drugstores, and more.

    China Grand Enterprises Pharmaceuticals & Healthcare (hereinafter referred to as CGE Healthcare) owns multiple subsidiaries such as Huadong Medicine, Grand Pharmaceutical Group, Lei Yunshang Pharmaceutical Group and Grand Biotech Group. The enterprise has a worldwide marketing network, working closely with over 10,000 Level II hospitals, over 50,000 basic medical institutions and top 100 drugstores.

    CGE Healthcare adheres to the business concept of "technology research-based, patients-centered and market-oriented" and has always taken innovation as the strategic focus. New products have been consistently put to market through the independent R&D platform construction, industry-teaching-research collaborative innovation and international cooperation, guaranteeing the enterprise's sustainable and rapid development. Through more than 20 years of development, the enterprise has formed a business model integrating R&D, production and sales, simultaneously developing traditional Chinese medicines, chemical medicines, biological medicines, medical devices and medical cosmetic; jointly developing domestic and international markets.

    Huadong Medicine

    With Huadong Medicine Co., Ltd. as the main body, Huadong Medicine has subsidiaries and production bases in cities including Hangzhou, Ningbo, Xi'an, and Yancheng. The main business covers the full pharmaceutical industry chain, led by the pharmaceutical industry while expanding to pharmaceutical business and medical cosmetology. The company is a well-known large-scale comprehensive pharmaceutical enterprise integrating pharmaceutical R&D, production and sales, modern pharmaceutical logistics, the health industry, and medical beauty product manufacturing and sales.

    The company has made a positive layout in innovative drugs with high technical barriers in three core treatment fields i.e., anti-tumor, endocrine and autoimmune and generic drugs; in the field of anti-tumor, it has established a partnership with Exscientia, a world leading artificial intelligence (AI) drug development company, to accelerate the discovery of groundbreaking innovative therapies for small molecule drugs in the field of cancer. In the field of pharmaceutical business, the company is the largest and most powerful comprehensive large pharmaceutical business enterprise in Zhejiang Province. Its business covers pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics with cold chain characteristics, pharmaceutical e-commerce, hospital value-added services and characteristic big health industry, providing customers with comprehensive solutions; for medical beauty business, it focuses on the R & D, production and sales of the latest products and devices in the field of facial micro plastic surgery and skin management. Sinclair, a wholly-owned subsidiary, has its headquarter in the UK and production bases in France and Netherland, and its core products have been marketed in more than 60 countries and regions around the world.

    The company has made a positive layout in innovative drugs with high technical barriers in three core treatment fields i.e., anti-tumor, endocrine and autoimmune and generic drugs; in the field of anti-tumor, it has established a partnership with Exscientia, a world leading artificial intelligence (AI) drug development company, to accelerate the discovery of groundbreaking innovative therapies for small molecule drugs in the field of cancer. In the field of pharmaceutical business, the company is the largest and most powerful comprehensive large pharmaceutical business enterprise in Zhejiang Province. Its business covers pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics with cold chain characteristics, pharmaceutical e-commerce, hospital value-added services and characteristic big health industry, providing customers with comprehensive solutions; for medical beauty business, it focuses on the R & D, production and sales of the latest products and devices in the field of facial micro plastic surgery and skin management. Sinclair, a wholly-owned subsidiary, has its headquarter in the UK and production bases in France and Netherland, and its core products have been marketed in more than 60 countries and regions around the world.

    The company has won multiple awards in recent years. The project "Key Technology for Industrialization of Acarbose Raw Materials and Preparations" tooks second prize at the National Science and Technology Progress Awards. With outstanding performance and good governance, the company has won a place among Forbes "Top 50 Best Listed Companies in Asia Pacific," "Top 100 Listed Companies on China's Main Board," and "Top 100 Listed Companies Most Respected by Investors in 2017" by China Association for Public Companies. In 2019, the company won such accolades as "Top 10 Chinese Pharmaceutical Listed Companies with the Biggest Investment Value," "Top 50 Companies in China with Strong Chemical Pharmaceutical R&D Capacity," "Top 100 Chinese Pharmaceutical Innovation Enterprises in 2019" and "Top 100 High-Tech Innovative Enterprises in Zhejiang Province in 2019," whilst remaining on the Fortune China 500 List for many years.

    Grand Pharmaceutical Group

    With Grand Pharmaceutical (China) Co., Ltd. as the main body, Grand Pharmaceutical Group has become a global comprehensive pharmaceutical enterprise mainly engaged in R&D, production and sales of pharmaceutical preparations, high-end medical devices, high-quality active pharmaceutical ingredients (API), biotechnology products and health products. The core products cover respiratory and otolaryngology (ENT) systems, and cardiovascular preparations in first aid and emergency care as well as several business areas represented by high-end medical devices, biotechnology products, and health products.

    In recent years, Grand Pharmaceutical has many leading barrier products and exclusive varieties in the field of respiratory and facial features, cardiovascular and cerebrovascular emergency medicine, and has become one of the Chinese industrial leaders; in the field of biotechnology products and health products, it has established a stable cooperative relationship with many overseas high-quality customers. So far, the company has become a leader in the field of precision interventional therapy at home and abroad, through Canada's Conavi vascular imaging diagnosis, German Cardionovum vascular intervention and Nanjing Kenny brand embolectomy stent nerve intervention, as well as the Australian Sirtex SIR-Spheres® Y [90Y] resin microspheres and the United States OncoSec's TAVO TM tumor intervention products, it has formed a "blood vessel, nerve and tumor" trinity of global "accurate diagnosis + treatment" strategic layout, gradually realizing the strategic planning of "heart and brain treatment", being a company engaged in the rare dual cross vascular intervention and tumor intervention field in China, and the unique pharmaceutical company with product distribution in coronary artery, arteriovenous fistula and peripheral areas.

    Grand Medical, a wholly-owned subsidiary headquartered in Australia, is a global R&D platform for Grand Pharmaceutical's antiviral and anti-infective activities, focusing on innovative drugs in the field of sepsis and parainfluenza. HIP, the core project, has been approved to carry out phase II clinical research for the treatment of COVID-19 ARDS and Ib for the treatment of sepsis in Australia. Grand Medical Co., Ltd. and Belgium eTheRNA, its holding company are jointly promoting the exclusive strategic cooperation of mRNA platform. The technology of mRNA vaccine platform will help Grand Pharmaceutical improve its product layout in the fields of tumor immunotherapy and infectious disease treatment.

    The company has been rated "Top 100 Enterprises in China's Pharmaceutical Industry" for many years, with more than 8000 employees, of which more than 60% of R&D personnel possess a Master's Degree or above. The company has continuously introduced multiple international professional pharmaceutical R&D experts from the United States, New Zealand, Australia, and India and experts in the professional field at home and abroad as long-term advisers.

    Leiyunshang Pharmaceutical Group

    Taking "Lei Yunshang" (with a history of nearly 300 years) as the unified brand, and "gathering various herbs and benefiting the people" as the mission, Lei Yunshang Pharmaceutical Group adheres to the brand idea of "300-year Lei Yunshang passes down health wisdom" and strictly follows the ancestral teachings of "selecting genuine medicinal materials to produce high-quality medicines," while inheriting and carrying forward the essence of the doctrine of seasonal febrile diseases. Based on traditional Chinese medicine and fully absorbing modern scientific and technological achievements, the group has become a large-scale traditional Chinese medicine group with unique advantages in many disease treatment fields.

    The product line of Lei Yunshang Pharmaceutical Group covers 7 clinical treatment fields, such as medicines for the respiratory system, medicines for the urinary system, tonics, medicines for the digestive system, gynecology and pediatrics medicines, medicines for cardiovascular and cerebrovascular diseases, and antineoplastic drugs. The main medicine covers many approved products by the National Medical Products Administration (NMPA), such as tablets, powders, granules, pills, capsules and ointments. The group has many products, national secret formulas and national protected varieties of traditional Chinese medicine. Moreover, the group has multiple products by application of two national top-secret formulas listed in the national intangible cultural heritage catalog, such as Liushen Pill, "national drug approval No.1" Jianyanling Capsule and Kuhuang series products, Capsule for Nourishing Lung & Activating Blood Circulation, Xiaozheng Pill, Lingbao Heart Protection Pill, and other important products. Meanwhile, the latest clinical and experimental data are provided for more scientific, standardized and precise application through cooperation and research with medical authorities at home and abroad. In the field of respiration, we cooperate with Zhong Nanshan academician team of the State Key Laboratory of Respiratory Diseases (Guangzhou Medical University) and elucidate the anti-inflammatory and antiviral mechanism of Liushen products by modern biomedical technology. In the field of digestion, through the international advanced artificial liver technology based on tissue engineering, the group clarifies the exact role and key mechanism of Kuhuang series products in endoplasmic reticulum emergency, oxidative damage, hepatic fibrosis, normalizing gallbladder to cure jaundice, reliving steatosis, immune regulation and reconstruction, liver regeneration and apoptosis. In the field of gynecology and pediatrics with Chinese medical characteristics, combining the methods of network pharmacology, serum metabolomics and molecular biology technology, we will comprehensively explore and clarify the possible mechanism of action and potential therapeutic targets of the Xiaozheng Pill in inhibiting hyperplasia of mammary glands. In the cardiovascular field with Chinese medical characteristics, we explore the protective mechanism of Lingbao Heart Protection Pill on the occurrence and development of atherosclerosis, and myocardial ischemia, as well as the exact role and key mechanism in inhibiting and improving bradycardia by multi-channel and multi-target treatment.

    Lei Yunshang Pharmaceutical Group is committed to combining traditional Chinese medicine prescriptions with modern pharmacology. This is accomplished through adjusting Chinese traditional medicine for precise treatment, realizing more scientific, standardized, and precise application of Chinese traditional medicine through scientific interpretation and clinical value exploration, providing more precise traditional Chinese medicine treatment methods and combined solutions for patients.

    Grand Life Science

    With the pharmaceutical market's continuous development, Grand Life Science is transforming from traditional biopharmaceutical to high-tech biopharmaceutical. Aiming at the latest international biotherapy targets, the company has developed a series of genetic engineering drugs such as antibodies, immunotherapeutic enzymes, therapeutic vaccines, and coagulation factors. Grand Life Science owns Hangzhou Grand Biologic Pharmaceutical INC., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.

    Hangzhou Grand Biologic Pharmaceutical INC. has bioengineering pharmaceutical technologies and production bases based on microorganism, the company's leading product "Bifidobacterium Tetravaccine Tablets(live) (Siliankang)", obtaining an independent invention patent, has the function of reconstructing intestinal flora and is widely used in the treatment of digestive system diseases. The type of viable bacteria in the product conforms to the relevant guidelines of WHO. The efficacy and safety of Bifidobacterium Tetravaccine Tablets(live) (Siliankang) has been widely recognized in clinical practice and successfully included in the 2019 catalog of medicines covered by the national medical insurance system. The research projects conducted by the enterprise utilization of modern biotechnology will make greater contributions to the development of microecologics in China.

    Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (hereinafter referred to as SHUYANG), one of the first batch of China's designated blood products production enterprises, is in the leading position in the industry relying on its comprehensive strength. The company owns eight products series, among which Human Hepatitis B Immunoglobulin for Intravenous Injection is the pioneer product in Asia, and the life cycle of patients with liver transplantation is significantly prolonged through its clinical application in the perioperative period of liver transplantation, and Human Hepatitis B Immunoglobulin for Intravenous Injection was awarded the title of "National Key New Product". The self-developed technology of viruses double-sterilized without adding any protective agent has obtained patents from China, the United States, and other countries. The company is China's leading blood products export enterprises with products all over the country. In 2016, SHUYANG worked with world-famous enterprises IBM and Rockwell to establish a demonstration base for the integration of deep automation and high informatization of sterile products. After the completion of the project, the product quality standards will meet the EU, U.S. FDA, and domestic GMP certification, and meet the WHO standards. Moreover, the demonstration base will become the world's leading blood product enterprise with the largest monomer production capacity in Asia and the world's top ten R&D planning of variety structure, and a biomedical platform for launching international cutting-edge monoclonal antibodies.

    Liaoning Grand Nuokang Biopharmaceutical Co., Ltd. focuses on perioperative management and wound management products as well as the development of comprehensive solutions and works on providing original biopharmaceuticals, complicated high-end preparations, and medical devices with biodegradable materials. The company has a professional R&D center concentrating on innovative drugs and medicines, and high-technical-barrier emulsion R&D center, enzyme engineering as well as medical device R&D and production transformation platform, with corresponding comprehensive modern production bases of various preparations, active pharmaceutical ingredients (API) base and Peru snake venom supply base.

    The company is committed to providing original biopharmaceuticals, complicated high-end preparations and medical devices with biodegradable materials. The core products include Baquting®, Kaitong®, Fu Dingle®, Aido®, ROPION®, collagenase, PPDO suture, etc. Hemocoagulase Atrox for Injection (Baquting®) has obtained the Chinese invention patent (pharmaceutical composition patent), and the national drug standards of the product has been formulated. It is the only snake venom hemostatic drug recorded in the Chinese Pharmacopoeia, setting a new milestone for China's hemostatic drugs. Flurbiprofen Axetil Injection (ROPION®) is mainly used for postoperative and cancer analgesia. It is the first special injection that has passed the consistency evaluation in China and the first injection selected in the Catalog of Chinese Marketed Drugs. Collagenase for Injection is a national Class 1 new drug, the only enzyme drug recommended by expert consensus for the treatment of lumbar disc herniation. Collagenase Ointment is the "national Class 3.1" drug, the only enzyme drug for debridement officially approved by FDA, and the exclusive national product.

    0e4075dce72c29199d483de5c00c5651752150.jpg

    With the acceleration of China's medical system reform, guided by the enterprise spirit of "loyalty, simplicity, diligence and innovation", CGE Healthcare will adhere to the principle of quality first and development through innovation, always take "serving the society" as the highest mission, expand future business through innovative cooperation, and continuously make contributions to the society.